Table 1.
Clinical and Pathological Features of Patients Diagnosed as MCB
| Characteristics | Total Set (n=4326) | Training Set (n=3030) | Validation Set (n=1296) |
|---|---|---|---|
| Age, years | |||
| <72 | 2680(62.0%) | 1860(61.4%) | 820(63.3%) |
| 72–82 | 1179(27.3%) | 841(27.8%) | 338(26.1%) |
| >82 | 467(10.8%) | 329(10.9%) | 138(10.6%) |
| Tumor size, mm | |||
| <13.0 | 1559(36.0%) | 1099(36.3%) | 460 (35.5%) |
| 13.0–27.0 | 1826(42.2%) | 1269(41.9%) | 557(43.0%) |
| >27.0 | 941(21.8%) | 662(21.8%) | 279(21.5%) |
| Race | |||
| White | 3260(75.4%) | 2319(76.5%) | 941(72.6%) |
| Black | 535(12.4%) | 351(11.6%) | 184(%14.2) |
| Other | 531(12.3%) | 360(11.9%) | 171(13.2%) |
| Grade | |||
| I | 2577(59.6%) | 1820(60.1%) | 757(58.4%) |
| II | 1579(36.5%) | 1087(35.9%) | 492(38.0%) |
| III | 167(3.9%) | 120(4.0%) | 47(3.6%) |
| IV | 3(0.1%) | 3(0.1%) | 0 |
| AJCC | |||
| I | 2733(63.2%) | 1910(63.0%) | 823(63.5%) |
| II | 1388(32.1%) | 975(32.2%) | 413(31.9%) |
| III | 156(3.6%) | 110(3.6%) | 46(3.5%) |
| IV | 49(1.1%) | 35(1.2%) | 14(1.1%) |
| T stage | |||
| T1 | 1805(64.8%) | 1955(64.5%) | 85,065.6(%) |
| T2 | 1242(28.7%) | 871(28.7%) | 371(28.6%) |
| T3 | 220(5.1%) | 163(5.4%) | 57 (4.4%) |
| T4 | 59(1.4%) | 41(1.4%) | 18(1.4%) |
| N stage | |||
| N0 | 3908(90.3%) | 2750 (90.8%) | 1158(89.4%) |
| N1 | 339(7.8%) | 227(7.5%) | 112(8.6%) |
| N2 | 53(1.2%) | 33(1.1%) | 20(1.5%) |
| N3 | 26(0.6%) | 20(0.7%) | 6(0.5%) |
| M stage | |||
| M0 | 4277(98.9%) | 2995(98.8%) | 1282(98.9%) |
| M1 | 49(1.1%) | 35(1.2%) | 14(1.1%) |
| Surgery | |||
| No | 149(3.4%) | 108(3.6%) | 41(3.2%) |
| Yes | 4177(96.6%) | 2922(96.4%) | 1255(96.8%) |
| Radiotherapy | |||
| No | 2085(48.2%) | 1443(47.6%) | 642(49.5%) |
| Yes | 2241(51.8%) | 1587(52.4%) | 65,450.5(%) |
| Chemotherapy | |||
| No | 3749(86.7%) | 2637(87.0%) | 111,285.8(%) |
| Yes | 577(13.3%) | 393(13.0%) | 184(14.2%) |
| Bone metastasis | |||
| No | 4295(99.3%) | 3008 (99.3%) | 1287(99.3%) |
| Yes | 31(0.7%) | 22(0.7%) | 9(0.7%) |
| Brain metastasis | |||
| No | 4321(99.9%) | 3026(99.9%) | 1295(99.9%) |
| Yes | 5(0.1%) | 4(0.1%) | 1(0.1%) |
| Liver metastasis | |||
| No | 4316(99.8%) | 3023(99.8%) | 1293(99.8%) |
| Yes | 10(0.2%) | 7(0.2%) | 3(0.2%) |
| Lung metastasis | |||
| No | 4303(99.5%) | 3015(99.5%) | 1288(99.4%) |
| Yes | 23(0.5%) | 15(0.5%) | 8(0.6%) |
| ER | |||
| Negative | 49(1.1%) | 34(1.1%) | 15(1.2%) |
| Positive | 4277(98.9%) | 2996(98.8%) | 1281(98.8%) |
| PR | |||
| Negative | 341(7.9%) | 237(7.8%) | 104(8.0%) |
| Positive | 3985(92.1%) | 2793(92.2%) | 1192(92.0%) |
| HER2 | |||
| Negative | 4094(94.6%) | 2862(94.5%) | 1232(95.1%) |
| Positive | 232(5.4%) | 168(5.4%) | 64(4.9%) |
| Marital status | |||
| No | 697(16.1%) | 475(15.7%) | 222(17.1%) |
| Yes | 3629(83.9%) | 2555(84.3%) | 1074(82.9%) |
Abbreviations: MCB, mucinous carcinoma of the breast; AJCC, American Joint Committee on Cancer; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor 2-neu.